its number of shareholders falls below 300 or if it has fewer than 500 shareholders and assets of less than
$10 million.
Liability
Section 10(b) (and Rule 10b-5) prohibit fraud in connection with the purchase and sale of any security,
whether or not the security is registered under the 1934 Act.
Section 10(b)
Section 10(b) of the 1934 Act prohibits fraud in connection with the sale of any security, whether or not
registered under the 1934 Act. The SEC adopted Rule 10b-5 to implement Section 10(b). Liability under
Rule 10b-5 requires:
A misstatement or omission of a material fact in connection with a securities
transaction,
Scienter (i.e., willful, knowing, or reckless disregard of the misstatement of
fact),
Purchase or sale of a security,
Reliance on the misstatement or omission,
Economic loss to the plaintiff, and
The loss must have been caused by the misstatement or omission of fact.
Case: Matrixx Initiatives, Inc. v. Siracusano
Facts: Zicam Cold Remedy was a nasal spray (or gel) that accounted for 70 percent of Matrixx’s sales
revenue. Its active ingredient was zinc gluconate. Matrixx began receiving reports that some Zicam users
had developed anosmia (that is, they had lost their sense of smell). The company learned for the first time
that some studies had linked the use of zinc sulfate to the loss of smell.
Matrixx then found out that two doctors were planning to make a presentation at a conference about
patients who had developed anosmia after Zicam use. Matrixx sent them a letter warning them that they
did not have permission to use the name of Matrixx or its products. The doctors deleted references to
Zicam.
Nine people filed suit against Matrixx, alleging that Zicam had damaged their sense of smell. Matrixx
then issued statements that Zicam was poised for growth and that revenues would increase by more than
80 percent. In its 10-Q filing with the SEC, Matrixx warned of the potential “material adverse effect” that
could result from product liability claims, “whether or not proven to be valid.” It did not disclose,
however, that plaintiffs had already sued Matrixx.
After the Food and Drug Administration (FDA) announced that it was investigating Zicam, Matrixx’s
stock price fell. The company issued a press release stating that there are many causes for anosmia,
including the common cold, but Zicam was not one of them.
The day after this press release, Matrixx stock price bounced back. Shortly thereafter, however, the
TV show Good Morning America reported that more than a dozen patients had suffered from anosmia
after using Zicam and that some had filed lawsuits against Matrixx. The company’s stock price
plummeted.
A group of shareholders filed suit, alleging that Matrixx had violated Section 10(b) and Rule 10b-5.
The trial court granted Matrixx’s motion to dismiss on the grounds that, without a statistical correlation
between the use of Zicam and anosmia, the reported incidents were not material. The Court of Appeals
reversed. The Supreme Court granted certiorari.
Issues: Did Matrixx violate §10(b) and Rule 10b-5?
Decision: Yes, Matrixx was in violation.